2022-02-18-MLNC-SE

Date
2022-02-18
Title
Special Edition - COVID-19 Monoclonal Antibodies: FDA Authorized Bebtelovimab



SPECIAL EDITION

Friday, February 18, 2022

 

COVID-19 Monoclonal Antibodies: FDA Authorized Bebtelovimab

On February 11, the FDA authorized the emergency use (PDF) of the monoclonal antibody bebtelovimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients when all of these apply:

  • They have a positive COVID-19 test result
  • They’re at high-risk for progression to severe COVID-19
  • Alternative COVID-19 treatment options approved or authorized by the FDA aren’t accessible or clinically appropriate for them

CMS created new codes, effective February 11:

Q0222:

  • Long descriptor: Injection, bebtelovimab, 175 mg
  • Short descriptor: Bebtelovimab 175

M0222:

  • Long Descriptor: Intravenous injection, bebtelovimab, includes injection and post administration monitoring
  • Short Descriptor: Bebtelovimab injection

M0223:

  • Long Descriptor: Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency
  • Short Descriptor: Bebtelovimab injection home

Visit the COVID-19 Monoclonal Antibodies webpage for more information.

 

Report a problem viewing this newsletter.

Subscribe to the MLN Connects® newsletter. Previous issues are available in the archive.

This newsletter is current as of the issue date. View the complete disclaimer.

Follow the MLN on Twitter #CMSMLN, and visit us on YouTube.

The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered trademarks of the U.S. Department of Health and Human Services (HHS).